Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

British Journal of Cancer

Volumn 101, Issue 11, 2009, Pages 1833-1838

  Heijnsdijk, E A M ^a   Der Kinderen, A ^a   Wever, E M ^a   Draisma, G ^a   Roobol, M J ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Overdetection; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CANCER THERAPY; CONTROLLED STUDY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED KINGDOM; UNITED STATES;

AGED; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 70649106303     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605422     Document Type: Article

References (23)

1. Beemsterboer PM, de Koning HJ, Birnie E, van der Maas PJ, Schroder FH (1999) Advanced prostate cancer:course, care, and cost implications. Prostate 40:97-104
2. Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH, Hogan C, Hayman JA (2002) Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 20:2869-2875
3. Chelladurai AJ, Gunendran T, Nicholson C, Matanhelia SS, Blades RA (2008) The economic and workload impact of 'backdoor' prostate-specific antigen screening on the UK National Health Service:a single-centre experience. BJU Int 101:289-292
4. Crawford ED, Abrahamsson PA (2008) PSA-based screening for prostate cancer:how does it compare with other cancer screening tests Eur Urol 54:262-273
5. Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schroder FH, Klein EA (2008) Validation of pretreatment nomograms for predicting indolent prostate cancer:efficacy in contemporary urological practice. J Urol 180:150-154
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening:estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878
7. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (2009) Lead time and overdiagnosis in prostate-specific antigen screening:importance of methods and context. J Natl Cancer Inst 101:374-383
8. Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ (2006) Gleason score, age and screening:modeling dedifferentiation in prostate cancer. Int J Cancer 119:2366-2371
9. Ekwueme DU, Stroud LA, Chen Y (2007) Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis 4:A100
10. Makhlouf AA, Boyd JC, Chapman TN, Theodorescu D (2002) Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology 60:656-660
11. Malmberg I, Persson U, Ask A, Tennvall J, Abrahamsson PA (1997) Painful bone metastases in hormone-refractory prostate cancer:economic costs of strontium-89 and/or external radiotherapy. Urology 50:747-753
12. Mols F, Korfage IJ, Vingerhoets AJ, Kil PJ, Coebergh JW, Essink-Bot ML, van de Poll-Franse LV (2009) Bowel, urinary, and sexual problems among long-term prostate cancer survivors:a population-based study. Int J Radiat Oncol Biol Phys 73:30-38
13. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, de Koning HJ (2003) Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 105:394-399
14. Perez CA, Michalski J, Ballard S, Drzymala R, Kobeissi BJ, Lockett MA, Wasserman TH (1997) Cost benefit of emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39:875-883
15. Poos MJJC, Smit JM, Groen J, Kommer GJ, Slobbe LCJ (2008) Kosten van ziekten in Nederland 2005. RIVM:Bilthoven
16. Postma R, Schroder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH (2007) Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 52:89-97 (Pubitemid 46803013)
17. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 56:584-591
18. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
19. Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and over-diagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64:10-19
20. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer:the PRIAS study. Eur Urol 52:1560-1563
21. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schroder FH (2005) Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol 174:121-125
22. Visser O, van Leeuwen FE (2005) Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands. Eur J Cancer 41:2321-2330
23. Zappa M, Ciatto S, Bonardi R, Mazzotta A (1998) Overdiagnosis of prostate carcinoma by screening:an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 9:1297-1300